Lava Therapeutics NV 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
LAVA Therapeutics N.V. reported Q3 2025 results, highlighting progress on its acquisition by XOMA Royalty Corporation, significant workforce reductions, and the discontinuation of clinical programs LAVA-1207 and LAVA-1266.
LAVA Therapeutics N.V. announced a definitive agreement to be acquired by XOMA Royalty Corporation for $1.16 per share plus contingent value rights, alongside significant restructuring and program discontinuations.
LAVA Therapeutics reports a net loss of $3.479 million for Q1 2025, but benefits from a $5.2 million gain on debt extinguishment and continues its strategic review process.